Revenue and Profit Trends
Over the seven-year period ending March 2025, Alembic Pharma’s net sales have shown consistent growth, increasing from ₹3,935 crores in 2019 to ₹6,672 crores in 2025. This represents a compound annual growth rate (CAGR) of approximately 10.5%, reflecting the company’s expanding market presence and product portfolio. Total operating income mirrors this trend, as other operating income remained nil throughout the period.
Operating profit before depreciation and interest (PBDIT) excluding other income exhibited volatility, peaking at ₹1,480 crores in 2021 before moderating to ₹1,008 crores in 2025. The operating profit margin (excluding other income) declined from a high of 27.45% in 2021 to 15.11% in 2025, indicating rising costs or pricing pres...
Read More











